AllPennyStocks.com Moderna’s $2B Convertible-Note Deal To Focus On Oncology Growth, Debt Repayment – But Retail Calls It A ‘Bull Trap’
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Moderna’s $2B Convertible-Note Deal To Focus On Oncology Growth, Debt Repayment – But Retail Calls It A ‘Bull Trap’

The biotech firm announced plans to raise $2 billion through convertible notes, which could be increased to $2.3 billion.

Other Penny Stock Movers

$500 Million AI Merger Sends This Microcap Soaring
Historic Gold Ground Gets a Fresh Drill Test
Washington Is Financing Critical-Mineral Projects. What Will Canada Do?
Most Popular
{{ index + 1 }}
AllPennyStocks.com Favorites


Back to Top